
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis Inc. demonstrated a positive financial trajectory with a notable increase in gross margin, reaching 27.1% in 4Q24, which reflects a 50 basis points year-over-year improvement, driven by a favorable customer mix and increased biopharma volume. Revenue from biopharma testing and services surged by 59% to $51 million in 2024, underscoring strong demand and effective partnerships, particularly with Tempus. Furthermore, substantial growth in clinical test volumes by 53% in 2Q24 and 4Q24 illustrates the company's expanding market presence and its commitment to enhancing commercial capabilities ahead of anticipated reimbursement developments.
Bears say
Personalis Inc. reported a decline in operating expenses for 4Q24, yet this decrease does not offset the concerning drop in revenue, which decreased by 15% year-over-year, indicating potential issues in demand for its genomic sequencing services. The company's revenue from its VA MVP partnership saw a significant decline from $4.4 million in 3Q24 to only $0.2 million in 4Q24, highlighting a critical risk in maintaining essential contracts and revenue streams. Furthermore, the projected total revenues for 2025 have been revised downward to $86.9 million, a significant drop from prior estimates, signaling challenges in both biopharma customer adoption of new products and overall market growth in the clinical diagnostics sector.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares